PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 1
A PHASE 1, NON -RANDOMIZED, OPEN -LABEL, PARALLEL -GROUP 
SINGLE -DOSE STUDY TO EVALUA TE THE PHARMACOKINET ICS, SAFETY, 
AND TOLERABILITY OF INTRAVENOUS RIVIPANS EL (PF -06460031) IN 
SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT A ND IN HEALTHY 
SUBJECTS WITH NORMAL HEPATIC FUNCTION
Investigational Product Number: PF-06460031
Investigational Product Name: Rivipansel
United States (US) Investigational N ew 
Drug (IND) Number:77,984
European Clinical Trial sDatabase 
(EudraCT) Number:Not Applicable
Protocol Number: B5201006
Phase: 1
 
 
 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 2Document History
Document Version Date Sum mary of Changes
Original protocol 27June 2016 Not A pplicable ( N/A)
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 3TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................6
APPENDI CES ...........................................................................................................................6
SCHEDUL E OF ACTIVITI ES..................................................................................................7
1. INTRODUCTION ...............................................................................................................10
1.1. Mechanism of Action/I ndication .............................................................................10
1.2. Background .............................................................................................................10
1.3. Rationale ..................................................................................................................13
1.3.1. Study  Rationale ...........................................................................................13
1.3.2. Dose Rationale ............................................................................................13
2.STUDY OBJECTIVES AND ENDPOINTS .......................................................................13
3. STUDY DESIGN .................................................................................................................14
3.1. Study  Overview .......................................................................................................14
4. SUBJECT ELIGIBILI TY CRI TERIA .................................................................................15
4.1. Inclusion Criteria................................................................
.....................................16
4.1.1. All Subjects .................................................................................................16
4.1.2. Health y Subjects with Normal Hepatic Function .......................................16
4.1.3. Subjects with Hepatic I mpairment ..............................................................17
4.2. Exclusion Criteria................................................................
....................................17
4.2.1. All Subjects .................................................................................................17
4.2.2. Health y Subjects with Normal Hepatic Function .......................................19
4.2.3. Subjects with Hepatic I mpairment ..............................................................20
4.3. L ifesty le Requirements
...........................................................................................21
4.3.1. Meals and Dietary  Restrictions ...................................................................21
4.3.2. Alcohol, Caf feine and Tobacco ..................................................................21
4.3.3. Activity .......................................................................................................21
4.3.4. Contraception ..............................................................................................22
4.3.4.1. Females - Childbearing Potential ..............................................22
4.3.4.2. Males ................................
.........................................................22
4.4. Sponsor’s Qualified Medical Personnel ..................................................................23
5. STUDY TREATMENTS ................................ ................................ ................................ .....23
5.1. Allocation to Treatment ..........................................................................................23
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 45.2. Subject Compliance .................................................................................................23
5.3. I nvestigational Product Supplies .............................................................................24
5.3.1. Dosage Form and Packaging ......................................................................24
5.3.2. Preparation and Dispensing ........................................................................24
5.3.3. Administration ............................................................................................24
5.4. I nvestigational Product Storage ..............................................................................25
5.5. I nvestigational Product Accountabilit y...................................................................25
5.5.1. Destruction of Investigational Product Supplies
........................................26
5.6.Concomitant Treatment(s) .......................................................................................26
6. STUDY PROCEDURES
................................................................
.....................................26
6.1. Screening .................................................................................................................26
6.2. Study  Period ............................................................................................................28
6.2.1. Day  0................................................................
...........................................28
6.2.2. Day  1................................................................
...........................................29
6.2.3. Day  2................................................................
...........................................30
6.2.4. Day  3................................................................
...........................................30
6.2.5. Day  4................................................................
...........................................30
6.2.6. Day  5................................................................
...........................................30
6.3.Follow -upContact ................................................................
...................................31
6.4. Subject Withdrawal /Earl y Termination ..................................................................31
7. ASSESSMENTS ..................................................................................................................32
7.1. Safet y................................................................
.......................................................33
7.1.1. L aboratory  Tests .........................................................................................33
7.1.2. Phy sical Examinations ................................................................................34
7.1.3. Blood Pressure and Pulse Rate ...................................................................34
7.1.4. Temperature ................................................................................................35
7.1.5. Electrocardiogram .......................................................................................35
7.2. Pharmacokinetics ....................................................................................................35
7.2.1. Plasma fo r Pharmacokinetic Anal ysis of Rivipansel..................................35
7.2.2. Plasma for Unbound Fraction Determination of Rivipansel ......................36
7.3. Blood Volume ................................
.........................................................................37
8. ADVERSE EVENT REP ORTI NG......................................................................................37
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 58.1. Requirements ...........................................................................................................37
8.1.1. Additional Details on Recording Adverse Events on the CRF ...................38
8.1.2. Eliciting Adverse Event Information ..........................................................39
8.1.3. Withdrawal From t he Study  Due to Adverse Events (see also the 
Subject Withdrawal section) ............................................................................39
8.1.4. Time Period for Collecting AE/SAE I nformation ......................................39
8.1.4.1. Reporting SAEs to Pfizer Safety ...............................................39
8.1.4.2. Recording Non
-serious AEs and SAEs on the CRF .................39
8.1.5. Causality  Asses sment .................................................................................40
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities ..................40
8.2. Definitions
................................................................
...............................................40
8.2.1. Adverse Events ...........................................................................................40
8.2.2. Abnormal Test Findings .............................................................................41
8.2.3. Serious Adverse Events ................................
..............................................41
8.2.4. Hospitalization ............................................................................................42
8.3. Severity  Assessment ................................................................................................43
8.4. Special Situations ....................................................................................................43
8.4.1. Potential Cases of Drug -Induced Liver Injury............................................43
8.4.2. Exposure to the Investigational Product During Pregn ancy  or 
Breastfeeding, and Occupational Exposure
.....................................................45
8.4.2.1. Exposure During Pregnancy ......................................................45
8.4.2.2. Exposure During Breastfeeding ................................................47
8.4.2.3. Occupational Exposure .............................................................47
8.4.3. Medication Errors .......................................................................................47
8.4.3.1. Medication Errors ................................
......................................47
9. DATA ANALYSI S/STA TISTICAL  METHODS ...............................................................48
9.1. Sample Size Determination .....................................................................................48
9.2. Pharmacokinetic Analy sis.......................................................................................48
9.2.1. Plasma .........................................................................................................49
9.3. Safet y Anal ysis........................................................................................................49
9.4. I nterim Anal ysis......................................................................................................50
9.5. Data Monitoring Committee ...................................................................................50
10. QUALITY CONTR OL AND QUALITY ASSUR ANCE .................................................50
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 611. DATA HANDLING AND RECORD KEEPING .............................................................51
11.1. Case Report Forms/Data Collection Tools/Electronic Dat a Record .....................51
11.2. Record Retention ...................................................................................................51
12. ETHI CS..............................................................................................................................52
12.1. I nstitutional Review Board/Ethics Committee ......................................................52
12.2. Ethical Conduct of the Study ................................................................................52
12.3. Subject I nformation and Consent ..........................................................................52
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................53
13. DEFI NITION OF EN D OF TRIAL ...................................................................................53
13.1. End of Trial in the United States ...........................................................................53
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................53
15. PUBLICATION OF S TUDY RESUL TS..........................................................................54
15.1. Communication of Results by  Pfizer ....................................................................54
15.2. Publications by  Investigators ................................................................................54
16. REFERENCES ..................................................................................................................56
LIST OF TABLES
Table 1. Assessment of Hepatic Impairment: Child -Pugh Score .......................................14
Table 2. Safety  Laboratory  Tests ........................................................................................33
APPENDICES
Appendix 1.Determination of Encephalopathy  for the Calculation of the Child Pugh 
Score .....................................................................................................................58
Appendix 2. Abbreviations ......................................................................................................60
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 7SCHEDULE OF ACTIVI TIES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol.
The investigator may  schedule visits (unplanned visits) in addition to those listed on the schedule of activities table , in order to 
conduct evaluations or assessments required to protect the well -being of the subject.  
Visit Identifier ScreeningaDay 0 Day 1 Day
2Day
3Day
4Day
528-day Follow -up 
Phone Call
Hours Relative to Dosing 00.33 1 3 4 6 8 10 12 16 24 48 72 96
Informed consent X
Inclusion/exclusion criteria X X
CRU confinement X             
Medical history X Xb
Medication history X X
Physical examinationcX X X
Demography X
Heightdand Weight X
Alcohol TesteX X
Child -Pugh ClassificationfXhX
Ascites evaluationfXhX
Encephalopathy Grade e valuationf,gXhX
Serologic tests: HIV -1 antibody , HBsAg and HCV antibody X
Safety laboratory testsiX X X
Reproductive status X
Contraception check X X
Serum FSHjX
Urine drug test X X
Supine 12 -lead electrocardiogram (ECG) X XkX
Single supine blood pressur e/pulse rateandtemperature X XkXmXl,mXl,mX X
Study medication administration after fasting for at least 4 hours X
Serious and non -serious a dverse event monitoring X               X Xp
Insertion of intra venous catheternXk
Standardized meals X X X X X X X X
Concomitant treatment(s) X            X
Blood sample for determina tion of rivipansel unbound fractionoX
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 8Visit Identifier ScreeningaDay 0 Day 1 Day
2Day
3Day
4Day
528-day Follow -up 
Phone Call
Hours Relative to Dosing 00.33 1 3 4 6 8 10 12 16 24 48 72 96
Discharge from CRU X
Abbreviations: = ongoing/continuous event; CRU = clinical research unit; FSH =follicle -stimulating hormone; HIV = human immunodeficiency virus; 
HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus ; INR = international normalized ratio; PT = prothrombin time
a.Subject w ill be screened w ithin 28 days prior to ad ministration of study medication .  For hepatic impair ment subjects, see footnote f.
b.On Day 0, review changes in medical history since screening visit.
c.Full physical examination at s creening and on Day 5, limited physical examination on Day 0.
d.Height measurement on ly at screening when fullphysical examination is performed.
e.Breath or blood alcohol test (method based on discretion of the investigator) for hepatic impairment subjects.  For healthy s ubjects, the alcohol test can be 
done at the discretion of the investi gator.
f.Hepatic impairment subjects only: Child -Pugh classification, encephalopathy grade and ascites evaluations to be performed w ithin the 14 days prior to 
administration of study medication .
g.Encephalopathy grade evaluation includes number connection te
st and blood ammonia level (Described in Appendix 1).
h.Second screening visit to be performed for hepatic impairment subjects if a subject is not able to provide documentation of stable h epatic disease (ie, copy of 
recent lab tests, in addition to medical chart) within the last 30 days ( no worsening clinical signs of hepatic impairment, or no w orsening of total bilirubin or 
prothrombin time by more than 50%).  See Screening section for details.
i.Includes chemistry, hematology (including PT/INR) and urinalysis ,and after fasting for at least 4 hours .
j.To be conducted for females who have achieved postmenopausal status, defined as cessation of regular menses for at least 12 consecutive months with no 
alternative pathological or physiological cause.  
k.Pre-dose.
l.The Day 1 Hour 4 and Hour 8 vital signs will be collected on the source document only.
m.Temperature does not need to be collected at this tim epoint.
n.Insertion of the intravenous catheter for collection of blood samples is optional.
o. Sam ple will be analyzed only if a pharmacokinetic difference in subject groups is observed.
p.Each subject will have a follow up phone call no earlier than 28 days and no later than 31 days after study drug admin istration to assess for adverse events 
(AEs) and serious adverse events (SAEs).
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 9Pharmacokinetic Sampling Schema
Visit Identifier 1 2 3 4 5
Hours After Dose 0 0.33 1 3 4 6 8 10 12 16 24 36 48 72 96
Study treatment administration X
Pharmaco kinetic blood sampling XaXbX X X X X X X X X X X X X
a.Pre-dose sample collection .
b.Timing of sample collection base don stop time of infusion of study medication .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 101.INTRODUCTION
1.1. Mechanism of Action/ Indication
Rivipansel is being developed as a pan -select in antagonist for the treatment of vaso- occlusive 
crisis ( VOC )in subjects with S ickle C ell D isease (SCD) and a Phase 3 study  is ongoing.
1.2.Background 
SCD is one of the most prevalent genetic disorders in the United States (US), affecting 
approximatel y 100 ,000 people.1  It is a chronic condition with substantial morbidity  and 
mortality , and is responsible for more than 75,000 hospitalizations per y ear in the US with an 
average in -patient stay of 6.1 days.2Both children and adults are affected, and greater 
mortality  is seen in those with more severe disease. 
SCD refers to a group of autosomal recessive inherited disorders of the hemoglobin -globin 
gene in which a sin gle nucleotide substitution results in the presence of valine instead of 
glutamic acid in the -globin chain and leads to the presence of Hemoglobin S (Hb S).  Hb S 
tends to poly merize when deoxy genated, this being the primary  indispensable event in the 
molecular pathogenesis of SCD.3  Individuals homozy gous for Hb S have sickle cell anemia 
(SCD -SS).  Those who are compound (double) heterozy gotes have 1 copy of the gene for 
HbS and 1 copy of the gene for either HbC (SCD -SC), Hb+-thalassemia (SCD -S+-thal), 
or Hb0-thalassemia (SCD -S0-thal).4
SCD is associated with a number of serious and potentially  disabling conditions that manifest 
similar sy mptoms although there may  be variat ion in severity  by genot ype.  Most notable is 
the VOC, an extremel y painful and serious consequence of SCD, resulting from acute 
ischemic tissue injury . 
Over the course of a year, about 60% of patients with SCD -SS will have at least 1 severe 
VOC,5which ty picall y presents as an episode of pain and inflammation, at 1 or more sites.  
VOC episodes occur with vary ing degrees of severity , and at vary ing intervals throughout 
life and, as the clinical hallmark of SCD, are responsible for the vast majority  of 
hospitalizations (>90%).  They  result in significant morbidity , interruption of daily  
functioning and mortality.  Other problems that occur in patients with SCD include ischemic 
and hemorrhagic stroke, acute chest s yndrome (ACS), splenic sequestration, dact ylitis, 
osteonecrosis, priapism, leg ulcers, and nephropathy .3,6,7,8Most SCD -related deaths occur 
during episodes of acute VOC, and are due to ACS or stroke.9Patients can become 
symptomatic with pain as earl y as 6 months of age; thus, VOCs a re an important cause of 
morbidity  throughout life, resulting in disruption to the individual’s psy chosocial 
development, education and employ
ment consequent upon the severe pain and the frequent 
need for hospitalization.  They  also potentially  contribute to premature death.
Current medical management of SCD includes hydroxyurea, which is used to increase fetal 
hemoglobin (Hb F) concentration with the aim of reducing the number of VOC’s.  Treatment 
of acute VOC includes mainly  supportive measures such as op ioid analgesics, hy dration and 
supplemental oxy gen.  There is no mechanism -based treatment currentl y available, so this 
remains an unmet medical need.  Most patients attempt pain management at home, and seek 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 11medical care onl y when this fails.  Therefore, m any painful episodes do not come to medical 
attention.10
The etiology  of VOC involves dual mechanisms: a mechanical component, by  which the 
sickled red blood cells (RBCs) become caught in the post- capillary  venules, and an 
associated inflammatory  component in which white blood cells (WBCs) adhere to the 
endothelium. Together, these 2 mechanisms lead to vascular occlusion and tissue ischemia.
Selectins are a famil y of adhesion molecules involved in trafficking and extravasation of 
leukocy tes.17During the inflammatory  response, leukocy tes extravasate from the 
bloodstream and migrate to the sites of inflammation where they  participate in the defense 
against pathogens o r other inflammatory  processes.  This recruitment of leukocy tes, which 
begins with the initial recognition and binding of the leukocytes to the endothelial cells that 
line the walls of the vasculature, is mediated b y selectins.18
Three selectins are known to bind carboh ydrate structures on cells in interactions 
characterized b y fast kinetics that allow cell adhesion to proceed under the shear forces of 
blood flow.19  
P-selectin is located on platelets and is also pre -formed and stored in 
Weibel -Palade bodies within the endothelial cells.  I t is a “first responder” and is expressed at 
the endothelial cell surface within 30 minutes of an acute inflammatory  response.20  
E-selectin is not pre -formed and stored, but requires de novo protein sy nthesis and is 
expressed on the endothelium 3 to 5hours after activation.21  Both of these sel ectins are 
responsible for the earl y recognition and adhesion of leukocy tes to the vascular endothelium.  
L-selectin is located on a subset of leukocy tes and participates in rolling and adhesion and 
plays a major role in homing to the ly mph nodes.17
Rivipansel is a pan- selectin antagonist, a compound found to inhibit selectin binding in vitro 
and to inhibit selectin -mediated effects in vivo.  There are no other known approved 
therapeutic agents in this class.
Pharmacokinetic (PK) data for rivipansel (GMI -1070) are available from 
2studies in healthy  
volunteers (GMI -1070- 101 and GMI -1070- 102), and from a third study  conducted in patients 
with SCD 18 to 50 years of age who, at the time of the study , were not exper iencing a VOC
(GMI -1070- 103). All of these studies were undertaken by  Glycomimetics (GMI), from 
whom Pfizer in -licensed rivipansel.  Rivipansel doses used in all GMI studies were based on 
the salt whereas in all Pfizer studies, including the current study, the dose will be based on 
the active moiet y of rivipansel.
In the first study  (GMI -1070 -
101), subjects received single intravenous ( IV)doses of
rivipansel 2, 5, 10, 20, or 40 mg/kg or placebo over 20 minutes.  I n the second study  
(GMI -1070- 102), subject s received multiple I V doses of rivipansel 5, 10, or 20 mg/kg or 
placebo every  8hours for a total of 13 doses.  An additional group of subjects received a 
loading dose of 40 mg/kg, followed by  multiple doses of rivipansel 20 mg/kg every  8hours 
for a tota l of 6 doses.  These studies evaluated a total of 72 health
y adult subjects 
(54rivipansel , 18placebo) .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 12Mean values for C max(maximum observed concentration) , AUC last(area under the 
concentration -time curve [AUC] from time 0 to the time of the last quantifiable 
concentration ), and AUC inf(AUC from time 0 to infinity ) increased in a dose -proportional 
manner, providing evidenc e of linear PK.  After a single 20 mg/kg dose, the mean standard 
deviation (SD) Cmaxwas 256 43.7 mg/L .  The time of peak concentra tion(Tmax)
corresponded to the time of the end of infusion and the collection of the first blood sample 
for determination of rivipansel .  The volume of distribution was consistent across dose levels, 
0.130 to0.181 L/kg.  Clearance was consistent across d ose levels (0.211 to
0.284 mL/min/kg) and the mean elimination half -life (t ½) ranged from 6.67 to 7.41 hours.  
Urine collection after multiple dose administration showed a minimum of 89% of the dose 
was recovered intact in the urine, and renal clearance (C Lr) was less than filtration clearance, 
consistent with tubular reabsorption.
The third study  (GMI -1070 -103) was an open -label study  of IV rivipansel in15adult 
subjects with stable SCD who received a loading dose of IV rivipansel 20 mg/kg over 
20minutes, followed 10 hours later b y a dose of IV rivipansel 10 mg/kg over 20 minutes.  
The PKwasobserved to be consistent with th atin the health y volunteers.
In these 3 studies ,there were no clinically  significant electrocardiogram (ECG) or phy sical 
exam inationfindings.  With 1 exception, all adverse events (AE) in subjects receiving 
rivipansel were Grade 1 or 2.  Severe s ymptomatic anemia (Grade 4) that occurred in 
1subject with stable SCD was considered to be remotely  related to the study  medication, and 
resolved with therap y.  No serious adverse events (SAE) were reported in these studies. 
B5201001, a thorough QT (time from ECG Q wave to the end of the T wave) study  in 
48healthy  African -American subjects who received a single dose of r ivipansel 4 gactive 
over 20 minutes, showed a lack of QTc (QT corrected for heart rate) effect.  There were no 
SAEs, no AE’s with clinical sequelae and no deaths due to AEs. No new Adverse Drug 
Reactions (ADRs) for rivipansel were identified in the study  but 1 subject disc ontinued the 
study  due to an AE of “alanine aminotransferase ( ALT) increased” following treatment with 
rivipansel.
A randomized, placebo -controlled Phase 2 trial (GMI -1070- 201), evaluating the efficacy , 
safet y, and PKof multiple IV doses of rivipansel in 76 subjects 12 to 60 years of age who 
were hospitalized for sickle cell VOC has also been under taken .  This study  included two 
dosing schedules; the first cohort received 20 mg/kg loading dose, then 10 mg/kg every  
12hours (q12 h)until 7 days, (maximum 15 doses) and the second cohort received 40 mg/kg 
loading dose, then 20 mg/kg q12 huntil 7 days, (maximum 15 doses).  
Each IV dose was 
administered over 20 minutes.  There were no clinically  significant ECG or clinical findings 
associated with cardiac toxic ity in these subjects.  Total treatment-emergent adverse event 
(TEAE) rates were comparable across groups.  SAE’s and those SAEs considered “related to 
treatment” were also comparable across groups.  Eleven (11 , 14.4% ) subjects discontinued 
study  drug due to AEs (8 subjects in the active group, and 3 subjects in the placebo group).  
No subjects discontinued the study  due to AEs.  A total of 28 SAEs were reported, 
encompassing 29 events across 23 subjects.  A 30% SAE rate was seen in both active and 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 13placebo groups.  The most common SAE was re- hospitalization for VOC.  No subjects died 
during the study .
Additional information for this compound may  be found in the single reference s afety 
document (SRSD), which for this study  is the Investigator Brochure (IB).
1.3.Rationale
1.3.1. Study Rationale 
Sickle cell disease can cause progressive injury  to the liver with fibrosis and decreased liver 
function by  adulthood .22  Although rivipansel is known to be primaril y eliminated by th e 
kidney  (>90% of dose excreted in urine based on data from the Single Ascending Dose study  
GMI -
1070- 101), hepatic function can have an effect on the PK of drugs for which the 
excretion is primaril y renal .  This study  is therefore being conducted to evalua te the effect of 
hepatic impairment on the PK, safet y and tolerability  of rivipansel.  Results from this study  
will be used in conjunction with collective safety , efficacy , and PK/ pharmacody namic ( PD)
data from other rivipansel 
studies to provide recommend ations on dosing for subjects with 
hepatic impairment.  
1.3.2. Dose Rationale
A single 840 mg dose of IV rivipansel will be used in this study  as it is the dose selected for 
maintenance dosing in the rivipansel Phase 3 program.  IV doses of rivipansel as high as
4 g(as a single dose) have been well tolerated in healthy  volunteers. In the Phase 2 study  
multiple doses, using a loading dose of 40 mg/kg followed by  doses of 20 mg/kg given every  
12hours for up to 7days were also well tolerated.  Therefore, it is e xpected that potential 
increases in exposure due to hepatic impairment with a single dose of 840 mg should not 
pose a safety  concern.  Single -dose administration was chosen because time -independent PK
ofrivipansel have been demonstrated at the anticipated concentrations, and thus single -dose 
PKwill be able to adequately  predict multiple -dose PK.
2. STUDY OBJECTIVES AND ENDPOINTS
Prim ary Objectives: Prim ary Endpoints:
To evaluate the effect of moderate hepatic 
impairm ent on the PK of rivipansel following a 
single 840 mg IV dose.
To evaluate the safety and tolerability of a 
single 840 mg IV dose of rivipansel in subjects 
with moderate hepatic impairment and in 
healthy subjects with normal hepatic function.Primary: AUC inf(or AUC last, as data permit ), 
CL.
Safety will be assessed by physical 
examinations, AE monitoring, 12 -lead ECGs, 
supine blood pressure ( BP) and pulse rate, and 
safety laboratory tests. 
Secondary Objective(s): Secondary Endpoint(s):
To evaluate the effect of moderate hepatic 
impairm enton ad ditional PK parameters for
rivipansel following a single 840 mg IV dose.Secondary: AUC last, Cmax, t½, Vss.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 143.STUDY DESIGN
3.1.Study Overview
This study is a Phase 1 open -label, single -dose, single -treatment, non -randomized study  of 
rivipansel in subjects with moderate hepatic impairment and health y subjects with normal 
hepatic function .  Since rivipansel is primarily  eliminated renall y, a reduced study  design 
with two groups (control subjects and subjects with moderate hepa tic impairment) was 
considered adequate to characterize the PKin subjects with hepatic impairment.
The Child- Pugh Score will be utilized to assess entry cr iteria and to assign subjects to the 
appropriate h epatic -impairment group.  Child -Pugh assessment s will be performed within the 
14days prior to study  medication administration and Day 0 (baseline).  S ubjects should 
satisfy  the criteria for Child -Pugh classification as Moderate Hepatic Impairment 
(Class BScore 7 -9) for both assessments in order to be enrolled into the study .  The subjects’
hepatic function will be ranked based on clinical signs and liver function test results 
(Table 1).
Table 1. Assessment of Hepatic Impairment: Child -Pugh Score
Assessment Param eters Assigned Score for Observ ed Findings
1point 2points 3points
Encephalopathy Gradea0 1or 2 3or 4
Ascites Absent Slight Moderate
Serum Bilirubin (mg/dL) <2 2to 3 >3
Serum Albumin (g/dL) >3.5 2.8to 3.5 <2.8
Prothrombin Time (seconds 
prolonged)<4 4to 6 >6
Classificati on of clinical severity:
Mild (Class A): Total score 5 -6points
Moderate (Class B): Total score 7 -9points
Severe (Class C): Total score >9 points
a.Grade 0: Normal consciousness, personality, neurological examination, electroencephalogram.
Grade 1: Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps(cycles per sec) 
waves.
Grade 2: Lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves.
Grade 3: Somnolent, stuporous, place- disoriented, hyperacti ve reflexes, rigidity, slow  waves.
Grade 4: Unrousable coma, no personality/behavior, decerebrate, slow  2-3cps delta activity.
SeeAppe ndix 1for details.
A total of approximatel y 16subjects will be enrolled; 8 subjects with moderate hepatic 
impairment and 8healthy  subjects with normal hepatic function. Healthy  subjects with 
normal hepatic function will be enrolled after all of the subjects with moderate hepatic 
impairment have completed the in -patient portio n of the study  and will be matched for age, 
weight, and gender to the mean demographics of subjects in the moderate hepatic impairment
group.  Health y subjects with normal hepatic function will be enrolled to enable comparison 
of PK parameters between heal thy subjects and subjects with moderate hepatic impairment.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 15Reasonable efforts will be made to enroll an adequate number of subjects (1 to 3subjects) 
with Child -Pugh scores of 8 or 9(based on assessment on Day 0) to ensure that the entire 
range of modera te hepatic impairment is represented.  
Subjects who withdraw from the normal hepatic function ormoderate hepatic impairment 
groups for non-safet y related reasons and who are considered to be non -evaluable with 
respect to the primary  PKobjective will be replaced at the discretion of the investigator and 
sponsor such that the number of completed subjects in each group equals eight .
Screening will occur within the 28 days prior to administration ofstudy  medication .  All 
subjects will provide informed conse nt and undergo Screening evaluations to determine their 
eligibility . 
Eligible subjects will be admitted to the Clinical Research Unit (CRU) on Day 0and will be 
confined in the CRU until Day 5.  On Day 1, subjects will receive a single 840 mg IV dose of 
rivipansel.  Serial blood samples will be collected at specified intervals for 96 hours 
post-dose for PKassessments, prior to discharge from the CRU on Day 5. 
Age/Weight/Gender Matching Criteria:
Subjects with Child -Pugh Class B (moderate) 
hepatic impair ment will be enrolled 
first and 
their demographics will be pooled.  Enrollment of age -, weight -, and gender -matched healthy  
subjects with normal hepatic function will begin after all of the moderate hepatic impairment 
subjects have completed the in -patient portion of the study .  Demographics of the healthy  
subjects will be matched to the pooled demographics of the moderate impairment group such 
that the body  weight of each healthy  subject is within 
15kg of the mean body  weight of the 
subjects with hepatic impairment, age is within 10years of the mean age of the subjects 
with hepatic impairment and the gender ratio for the group is similar ( 2subjects per gender) 
to the subjects with hepatic impairment.  I n general, care should be taken when recruiting t he 
healthy  subjects such that the entire group is as closely  matched as possible in age and bod y 
weight to the subjects with hepatic impairment .
Safety  assessments (as specified in the Schedule of Activities ) will be performed duri ng 
screening, prior to dosing on Day 1 and post dosing.  T he total participation time (ie, CRU 
confinement time for study  procedures) 
for each subject in this study  will be approximatel y 
5nights/6 days (excluding screening).   
Subjects will have a follow -up phone call no earlier 
than 28 days and no later than 31 daysafter study  drug administration, to assess for 
AEs/SAEs .
All procedures and their timelines follow the Schedule of Activities
.
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should b e taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 164.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the 
study :
4.1.1. All Subjects
1.Female subjects of non-childbearing potential or male subjects who, at the time of 
screening, are between the ages of 18 and 75 years, inclusive. 
2.Female subjects of non -childbearing potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal status, de fined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause and a serum follicle-stimulating hormone (FSH) level 
consistent with the post- menopausal state;  
b.Have undergone a docu mented hy sterectomy  and/or bilateral oophorectomy ;
c.Have medically  confirmed ovarian failure.
All other female subjects (including female subjects with tubal ligations) are
considered to be of childbearing potential.
3.Body  mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
4.Evidence of a personally  signed and dated informed consent document indicating that 
the subject has been informed of all pertinent aspects of the study .  
5. W
illing and able to comply  with all scheduled visits, treatment plan, laboratory  tests, 
and other stud y procedures.
4.1.2. Healthy Subjects with Normal Hepatic Function
1. H ealth y,defined as noclinically relevant abnormalities identified by  a detailed 
medical history , full phy sical examination, including BP and pulse ra temeasurement, 
12-lead EC G andsafety laboratory  tests.
2.
Normal hepatic function with no known or suspected impairment.
3.Demographically  comparable to subjects with hepatic impairment:
Body  weight will be within 15kg of the mean body  weight of the pooled group 
of subjects with moderate hepatic impairment.
Age will be within 10years of the mean age of the pooled group of subjects with 
moderate hepatic impairment.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 17The gender ratio for the group will be similar ( 2 subjects per gender) to the 
pooled group of subjects with moderate hepatic impairment.
4.1.3. Subjects with Hepatic I mpairment
1.Satisfy  the criteria for Child -Pugh classification as Moderate Hepatic Impairment 
(Class B - Score 7 -9) within the 14 days prior to ad ministration of study  medication
and Day 0 (baseline) [Note: As stated in the STUDY DESIGN section , reasonable 
efforts will be made to enroll an adequate number of subjects (1 to3subjects) with 
Child -Pugh scores of 8 and 9 (based on assessment at Day  0) to ensure that the entire 
range of moderate hepatic impairment is represented].
2. H epatic impairment due to primary liver disease and not secondary  to other diseases, 
confirmed and documented by  medical history , phy sical examination, liver biopsy ,
hepatic ultrasound, computed tomography  (CT) scan or magnetic resonance imaging 
(MRI).
3.Stable hepatic impairment, defined as no clinically -significant change in disease 
status within 
at least the last 30 days, (no worsening clinical signs of hepatic 
impairment, or no worsening of tot al bilirubin or prothrombin time by more than 
50%) as documented b y the subject’s recent medical history.  If subjects do not have 
adequate available records, 2 screening visits (Screening and Day 0visit) will be 
performed to demonstrate stability  of hepa tic disease.  The 2 visits (if performed) for 
demonstrating stability  of hepatic disease must be at least 7 days apart. 
4.On stable doses of medication and/or treatmen t regimens for at least 4 weeks prior to 
screening.  Such medications would also need to b e held stable from screening 
through study  completion.  Subjects who are receiving a fluctuating treatment 
regimen may  be considered for inclusion on a case- by-case basis if the underly ing 
disease is under control in the opinion of the investigator and sponsor.
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
4.2.1. All Subjects
1.
Known hy persensitivity  or intolerance to rivipansel .
2.History  of febrile illness within 5 days prior to ad ministration of study  medication .
3.Any medical or surgical condition that might significantly  interfere with the 
distribution, metabolism, or excretion of rivipansel.
4.A positive urine drug test for illicit drugs.  However, subjects with hepatic 
impairment who test positive for a prescribed medicine can be enrolled.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 185.History  of abuse of alcohol or binge drinking and/or any  other illicit drug use or 
dependence within 6months of s creening.  Binge drinking is defined as a pattern of 
5or more alcoholic drinks (male), or 4 or mo re alcoholic drinks (female) in about 
2hours.  As a general rule, alcohol intake should not exceed 2 drinks per day  or 
14drinks per week (1 drink = 5ounces of wine (150 mL) or 12 ounces (360 mL) of 
beer or 1.5 ounces (45 mL) of spirit).
6.Treatm ent with an investigational drug within 30days (or as determined by  the local 
requirement ) or 5 half-lives preceding the administration of study  medication
(whichever is longer) . 
7.Any prior history  of malignancy  with the exception of:
Basal cell carcinoma of the sk in; or 
Squamous cell carcinoma of the skin that has been recurrence-free for 
5years; 
or
Other malignancies (regardless of site) that have been recurrence -free for 
10years.
8.Pregnant or breastfeeding females ; male subjects with partners currentl y pregna nt; 
fertile m ale subjects who are unwilling or unable to use a highly  effective method of 
contraception as outlined in the protocol for the duration of the study  and for 28 days 
after the last dose of study  medication .
9.Use of herbal supplements within 28 d
ays prior to administration of study  medication .
10.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 56 days prior to administration of study  medication .
11.History  of sensitivity  to heparin or heparin -induced thrombocy topenia (if heparin is 
used to flush intravenous catheters). 
12.
An estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2based on the 
four-variable Modification of Diet in Renal Disease (MDRD) equation. 
13.Subjects who are unwilling or unable to co mply with the criteria in the Lifesty le 
Requirement ssection of this protocol.  
14. Subjects who are investigator site staff members directly  involved in the conduct of 
the study  (including their family  members
), site staff members o therwise supervised 
by the i nvestigator, or subjects who are Pfizer employ ees(including their family  
members )
,directly  involved in the conduct of the study .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 1915.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) o r active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the subject inappropriate for entry  into this 
study .
4.2.2. Healthy Subjects with Normal Hepatic Function
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
2.Screening supine 12- lead ECG demonstrating QTc F (QTc using Fridericia’s formula ) 
>450 msec or a QRS interval >120 msec at screening.  If QTc Fexceeds 450 msec, or 
QRS exceeds 120 msec , the ECG should be repeated two more times and the average 
of the three QTc For QRS values should be used to determine the subject’s eligibility .
3.Screening supine BP140mm Hg (sy stolic) or  90mm Hg (diastolic), on a single 
measurement following at least 5 minutes of rest.   
If BP is  140mm Hg (systolic) or 
90mm Hg (diastolic), the BP should be repeated two more times and the average of 
the three BP values should be use d to determine the subject’s eligibility .
4.History  of alcohol abuse with a positive alcohol test at screening oron Day 0at the 
discretion of the investigator.  
5.Subjects with ANY of the fol lowing abnormalities in safet ylaboratory  tests at 
screening, as a ssessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
Aspartate aminotransferase (AST) or alani ne aminotransferase (ALT) 
level >upper limit of normal (ULN);
Total bilirubin level  ULN .
6.Use of prescription dr ugs, vitamins, ordietary  supplements within 7 days or 
5half-lives (whichever is longer) prior to administration of study  medication .  As an 
exception, acetaminophen may be used at doses of 1g/day .  Limited use of 
nonprescription medications that are no t believed to affect subject safety  or the 
overall results of the study may  be permitted on a case -by-case basis following 
approval b y the sponsor.
7.Positive serolog
ic findings for human immunodeficiency  virus (HIV) antibodies, 
hepatitis B surface antigen ( HBsAg) and /or hepatitis C virus (HCV) antibodies. 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 204.2.3. Subjects with Hepatic Impairment
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, ps ychiatric, neurologic al, or allergic 
disease (including drug allergies, but excluding untreated, as ymptomatic, seasonal 
allergies at the time of dosing).
2.Hepatic carcinoma orhepatorenal s yndrome or life expectancy  less than 1 year.
3.Prior portal -caval shunt surgery .  A subject with a transjugular in trahepatic 
portosy stemic shunt (TIP S) is not excluded provided they meet the Child- Pugh 
criteria.
4.A positive alcohol test at screening or Day 0 (past history  of alcohol abuse is 
permissible providing that the results of alcohol tests are negative at screen ing and on 
Day 0).
5.History  of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less 
than 4 weeks prior to study  entry .
6.Any clinically -significant laboratory  abnormality  except for those parameters 
influenced b y hepatic impairment.
7.Positive serologic findings for human immunodefi ciency  virus (HIV) antibodies. 
8.Subjects with transaminases >5 ×upper limit of normal (ULN).  Subjects with 
transaminases >5 ×ULN may  be considered for inclusion on a case- by-case basis if, 
in the opinion of t he Investigator and Sponsor, these levels will not affect subject 
safet y.
9.Signs of significant hepatic encephalopath y (> Grade II Portal S ystemic 
Encephalopath y score).
10.Severe ascites and/or pleural effusion.
11. Prior kidney , heart or liver transplant .
12.Twelve (12)-lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec 
at screening.  If QTc Fexceeds 470 msec, or QRS exceeds 120msec ,the ECG should 
be repeated two more times and the average of the three QTcF or QRS 
values should 
be used to determine thesubject’s eligibility .
13. S creening s upine BP160mm Hg (sy stolic) or  90mm Hg (diastolic), on a single 
measurement follow ing at least 5 minutes of rest. If BP is  160mm Hg (sy stolic) or 
90mm Hg (diastolic), the BP should be repeated two more times a nd the average of 
the three BP values should be used to determine the subject’s eligibility .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 214.3.Lifestyle Requirement s 
The following guidelines are provided :
4.3.1. Meals and Dietary Restrictions
Subjects must abstain from all food and drink (except water) for at least 4 hours prior 
to any  safety laboratory  evaluations and to administration of study  medication .  Water 
is perm itted until 1 hour prior to study  medication administration.  Water may  be 
consumed without restriction beginning 1 hour after dosing.  Non -caffeinated drinks 
(except grapefruit or grapefruit- related citrus fruit juices – see below) may  be 
consumed with meals and the evening snack.
Breakfast will be provided approximatel y 1hour after dosing.
Lunch will be provided approximately  4hours after dosing.
Dinner will be provided approximatel y 9 to 10 hours after dosing.
An evening snack may be permitted.
Meals will be provided follow ingthe site’s normal schedule on non -dosing day s.
Subjects will not be allowed to eat or drink grapefruit or grapefruit -related citrus 
fruits (e g,Seville oranges, pomelos) from 7 days prior to the dose of study medication
until collection of the final PKblood sample. While in the clinical research unit 
(CRU ), the total daily  nutritional composition should be approximate ly 
55% carboh ydrate, 30% fat and 15% protein.  The daily  caloric intake per subject 
should not exceed approximately  3200 kcal.
4.3.2. Alcohol, Caffeine and Tobacco
Subje cts will abstain from alcohol f rom 24 hours prior to admission to the CRU until 
collection of the final PKsample.  Health y subjects with normal hepatic function may 
undergo an alcohol breath test or blood alcohol test at the discretion of the 
investigator.
Subjects will abstain from caffeine -containing products f rom 24 hours prior to the 
dose of study medication until collection of the final PKsample.  Subjects will 
abstain from the use of tobacco -ornicotine -containing products f rom 24 hours prior
to the dose of study  medication until the end of their confinement in the research unit.   
4.3.3. Activity
Subjects will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, and aerobics) for at least 48 hours prior to ea ch blood collection for 
safet ylaboratory  tests.  Walking at a normal pace will be permitted.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 224.3.4. Contraception
4.3.4.1. Fem ales - Childbearing Potential
Females of childbearing potential are excluded from participation.
4.3.4.2. Males
All fertile male subjects who are , in the opinion of the investigator, sexually  active and at risk 
for pregnancy  with their partner(s) must agree to use a highly  effective method of 
contraception consistently and correctl y for the duration of the active treatment period and 
for at least 28 daysafter the last dose of study  medication .  The investigator or his or her 
designee , in consultation with the subje ct,will confirm that the subject has selected an
appropriate method of contraception for the individual subject and his partner from the 
permitted list of contraception methods (see below) and will confirm that the subject has 
been instructed in its consi stent and correct use .  At time points indicated in the Schedule of 
Activities
, the investigator ordesignee will inform the subject of the need to use highly  
effective contraception consistently  and correctly  and document the conv ersation and the 
subject ’s affirmation in the subject’s chart (subjects need to affirm their consistent and 
correct use of at least 1 of the selected methods of contraception ).  In addition, the 
investigator ordesignee will instruct the subject to call im mediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject or
partner .  
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% pe r year when used consistently  and correctly  (ie,perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) provided subject or
male subject ’s female partner plans to remain on the same treatment throughout the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effectiveness.   
2. C orrectl y placed copper -containing intrauterine device (IUD). 
3.Male condom or female condom used WI TH a separate spermicide product (ie,foam, 
gel, film, cream, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highly  effective contraception, this o ption 
is not appropriate.
4.Male sterilization with absence of sperm in the post vasectomy  ejaculate.
5. B ilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the d evice’s label ).  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 23NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the usual and preferred 
lifesty le of the subject.
4.4.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study  contact list located in the team SharePoint site.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study  number s, 
contact inf ormation for the investigator site,and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from ano ther healthcare professional not involved in the 
subject ’s participation in the study . The contact number can also be used by  investigat or
staff if they  are seeking advice on medical questions or problems ; however, it should be used 
only in the event that the established communication path ways between the investigat orsite 
and the study  team are not available. It is therefore intended to augment, but not replace ,the 
established communication path ways between the investigat orsite and the study  team for 
advice on medical questions or problems that may arise during the study . For sites other than 
a Pfizer CRU, t he contact number is not intended for use b y the subject directly ,and if a 
subject calls that number ,he or she will be dire cted back to the inves tigatorsite.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni sation ( ICH)
guidelines
, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a refe rence /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further info rmation about an approved use (I CH E6 1.33).
For this study , the investigational product is r ivipansel (PF-06460031).  
5.1.Allocation to Treatment
The investigator will assign subject identification numbers sequentiall yto the subjects as 
they are screened fo r the study .  This identify ing number will be retained throughout the 
study .  All subjects enrolled will receive a single IV dose of rivipansel 840 mg on Day 1. 
5.2.Subject 
Compliance
Investigational product will be administered under the supervision of inve stigativesite 
personnel.  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 245.3. Investigational Product Supplies
5.3.1. Dosage Form and Packaging
Rivipansel (as the sodium salt) will be supplied by Pfizer in vials. Vials will contain 
rivipansel as a 30 mg/mL solution and the concentration of the solution is based on the active 
moiety .  Rivipansel is presented as a sterile, colorless to pale brown solution for single use
administration in a 30 mL clear glass vial sealed with a grey  stopper and aluminum over -seal
for administration by  intravenous infusion. The cont ent of the rivipansel vials should be
clear, but a fine swirl or haze of particulate matter may  be observed on agitation of the
solution.
Sterile vials will be packaged individually  and supplied for subsequent unit dose preparation 
according to the Investi gational Product Manual (IPM). Vial adapters and sy ringe filters will 
be supplied by  Pfizer for dose preparation.   
5.3.2. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the investigational product read y for administration or dispensing to the subject/caregiver b y 
qualified staff.  Dispensing is defined as the provision of investigational product, 
concomitant treatments, and accompan ying information by  qualified staff member(s) to a 
healt hcare provider, subject, or caregiver in accordance with this protocol.  L ocal health 
authority  regulations or investigator site guidelines may  use alternative terms for these 
activities.  
Rivipansel sterile solution for IV infusion will be prepared accor ding to details specified in 
the IPM.  This will include the requirement for the study  drug to be filtered through a 
0.22 micron sy ringe filter upon transfer to the s yringe that will be used for administration to 
the subject.  Investigational product shoul d be prepared and dispensed b y an appropriatel y 
qualified and experienced member of the stud y staff (eg, ph ysician, nurse, phy sician’s 
assistant, nurse practitioner, pharmacy  assistant/technician , or pharmacist) as allowed b y 
local, state, and institutiona l guidance .  
5.3.3. Administration
Following an overnight fast of at least 4 hours, subjects will receive investigational product 
at approximatel y 0800 hours (2hours).
Rivipansel will beinfused over 20 2 minutes using an administration set that includes a 
0.2or 0.22 micron in
-line filter.  The details of the IV infusion will be described in the IPM.  
The start and stop time of the infusion will be recorded.
In order to standardize the conditions on PKsampling day s, all subjects will be required to 
refrain f rom l ying down (except when required for 
BP, pulse rate, and ECG measurements)
during the first 4 hours after dosing.  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 255.4. Investigational Product Storage
The investigator, or an approved representative, eg, pharmacist, will ensure th at all 
investigational pr oducts are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements .  
Investigational product should be stored in its original container and in accordance with the 
label. See the IPM for storage conditions of the product.
Any storage conditions stated in the SRSD ( IBfor this study ) will be superseded b y the
storage conditions stated on the product label. 
Site staff will follow the standard operating procedure (SOP) for te mperature and relative 
humidity  monitoring in the CRU pharmacy .  
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, includ ing frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous monitoring sy stems, a log or site procedure that 
ensures active evaluation for
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non- working day s upon return to normal operations.  The operation of the 
temperature -
monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure it is maintaine d in working order. 
Any excursions from the product -label storage conditions should be reported to Pfizer upon 
discovery .  The site should actively  pursue optio ns for returning the product to thestorage 
conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer .  
Once an excursion is identified, the investigational product must be quarantined and not us ed 
until Pfizer provides permission to u se the investigational product.  It will not be considered a 
p
rotocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investig ational product prior to Pfizer approval will be 
considered a pro tocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site. 
5.5. Investigational Product Accountability
The investigat orsite must maintain adequate records documenting the receipt, use, los s, or 
other disposition of the 
investigational product supplies.  All investigational product s will be 
accounted for using a drug accountabilit y form/record. 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 265.5.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance o n the destruction of unused investiga tional 
product .  If destruction is autho rized to take place at the investigator site, the investigator 
must ensure that the materials are destro yed in compliance with applicable environmental 
regulations, institutional policy , and any  special instructions provided by  Pfizer ,and all 
destruction must be adequately documented.
5.6.Concomitant Treatment (s)
Health y subjects with normal hepatic f unction will abstain from all concomitant treatments, 
except fo r the treatment of AEs, as described in the Health y Subjects with Normal Hepatic 
Function section of this protocol
.  Use of p rescription drugs, vitamins, ordietary  supplements 
within 7 days or 5 half-lives (whichever is longer) prior to ad ministration of study  medication 
is not allowed .  As an exception, acetaminophen may  be used at doses of 1g/day .  Limited 
use of nonprescription medications that are not believed to affect subject safety  or the overall 
results of the study  may  be permitted on a case -by-case basis fo llowing approval by  the 
sponsor .
For subjects with impaired hepatic function, treatments intended for other indications should 
be administered as usual (Subjects with Hepatic I mpairment ). 
All concomitant treatmen ts taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration.  
Treatments taken within 28 days before the dose of investigational product will be 
documented as prior treatments.  Treatments taken after thedose of investigational product
will be documented as concomitant treatments .  
6.STUDY PROCEDURES
6.1.Screening
Subjects will be screened within 28 days prior to administration of investigational product to 
confirm that they meet the subject eligibility criteria for the study .  The investigator (or an 
appropriate delegate at the investigator site) will obtain informed consent from each subject 
in accordance with the procedures described in the Subject Information and Consent section.  
If the time between screening and dosing exceeds 28 days as a result of unexpected delay s 
(eg, delay ed drug shipment), then subjects do not require re -screening if the Day 0laboratory  
results meet the eligibility  criteria.
The following procedures will be completed:
Obtain written informed consent .
Confirm and document that the subject meets inclusion and exclusion criteria .
Collect demograph y.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 27Collect height and weight.
Obtain medical history , including history  of illegal drug, alcohol and tobacco use .
Obtain c omplete medication history  of all prescription or nonprescription drugs, and 
dietary  and herbal supplements taken within 28 days prior to the planned first dose.
Check reproductive status.
Perform c ontraception check.
Obtain single s
upine BP, pulse rate andtemperature .
Conduct full physical examination.  
Perform supine 12-lead electrocardiogram (ECG) .
Following at least a 4
-hour fast, collect blood and urine specimens for the following:
Safety  laboratory  tests ;
Serologic tests: HIV -1 antibody , HB sAg and HCV antibody ;
Urine drug test ;
Serum FSH concentration for an y female subject who has been amenorrheic 
for at least 
12consecutive months with no alternative pathological or 
physiological cause .
Obtain breath or blood alcohol test (method based on discretion of the investigator) 
for hepatic impairment subjects.  For health y subjects, the alcohol test can be done at 
the discretion of the investigator.  
Assess sy mptoms by  spontaneous reporting of AEs and by  asking the subjects to 
respond to a non- leading question such as “How do y ou feel?”
Hepatic impairment subjects only : Perform Child-Pugh classification, encephalopathy 
and ascites evaluation s within the 14 days prior to administration of study  medication . 
Encephalopath y grade evaluation includes number connection test and blood 
ammonia level. Subjects should s atisfy  the criteria for Child -Pugh classification as 
Moderate Hepatic Impairment ( Class B -Score 7 -9). Perform a second screenin g 
visit for hepatic impairment subjects if a subject is not able to provide documentation 
of stable hepatic disease (ie, cop y of recent laboratory tests, in addition to medical 
chart ) within the last 30 days (no worsening clinical signs of hepatic impairment, or 
no worsening of total bilirubin or prothrombin time b y more than 50%).  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 28To prepare for stud y participation, subjects will be instructed on the information in the
Lifesty le Requirement sand Concomitant Treatment (s)sections of the protocol.  
6.2.Study Period
For the study  period described below, when multiple procedures are scheduled at the same 
time point(s) relative to dosing, the following chronology of events should be adhered to, 
where possible.
ECGs: obtain prior to vital signs measurements and as close as possible to the 
scheduled time, but prior to blood specimen collection;
BP/pulse rate : obtain as close as possible to the scheduled time, but prior to blood 
specimen collection;
PKblood specimens : obtain at the scheduled time;
All o ther procedures : obtain as close as possible to the scheduled time, but may  be 
obtained before or after blood specimen collection .
When an IVcatheter is utilized for blood sample collections, ECGs andvital sign (pulse rate
andBPandt
emperature) assessments should be collected prior to the insertion of the 
catheter.
6.2.1. Day 0
Subjects will be admitted to the CRU on Day 0.The following procedures will be completed
following admission to the CRU:
Review i nclusion and e
xclusion criteria.
Review changes in the subject’s medical his tory including medication history since 
screening .
Conduct l imited physical examination .
Obtain breath or blood alcohol test (method based on discretion of the investigator) 
for hepatic impairment subjects.  For health y subjects, the alcohol test can be do ne at 
the discretion of the investigator
.  
Obtain blood and urine samples for safet y laboratory tests after fasting for at least 
4hours .  The results must have no clinicall y significant findings, as judged by the 
investigator, in order for a subject to b e given study  medication on Day 1.
Collect urine for drug testing.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 29Hepatic impairment subjects only : Re-perform Child -Pugh classification (considered 
as baseline score) , encephalopathy  and ascites evaluations. Encephalopathy grade 
evaluation includes nu mber connection test and blood ammonia level . Subjects 
should s atisfy  the criteria for Child -Pugh classification as Moderate Hepatic 
Impairment (Class B - Score 7 -9).  
Assess baseline s ymptoms/AEs.
Provide s tandardized meals as described in the Lifesty le Requirement ssection .  
Subjects will begin fasting at least 4 hours prior to dosing on Day 1.
6.2.2. Day 1
Prior to dosing, the following procedures will be completed: 
Collect supine 12- lead ECG.
Obtain singl e supine BP, pulse rate and temperature .
Insert the IVcatheter for collection of blood samples (
optional ).
Collect a blood sample for PK analysis.
Commence concomitant treatment monitoring.
Assess
baseline s ymptoms/AEs.
After all pre -dose procedures have been completed and afte r fasting for at least 
4hours , administer the study  medication (see the STUDY TREATMENTS and 
Administration sections). 
After dosing
, the following procedures will be completed:
Collect blood sample sfor PKanalysisof rivipansel 0.33, 1, 3, 4, 6, 8, 10, 12 and 
16hours after dosing.
Collect b lood sample sfor determination of rivipansel unbound fraction 1 hour after
dosing .  
Obtain 
single supine BPand pulse rate 1, 4 and 8 hours after dosing.  Hour 4 and 
Hour 8 collection swill be documented on source document only .
Assess sy mptoms by  sponta neous reporting of AE s and by  asking the subjects to 
respond to a non
-leading question such as “How do y ou feel?”
Monitor concomitant treatments.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 30Provide s tandardized meals 1, 4, and 10 hours after dosing as described in Lifesty le 
Requirement ssection.
6.2.3. Day 2
The following procedures will be completed:
Collect blood sample sfor PKanalysis24and 36 hours after dosing on Day 1.
Obtain single supine BP, 
pulse rate andtemperature .
Assess sy mptoms by  spontaneous reporting of AEs and by  asking the subjects to 
respond to a non- leading question such as “How do y ou feel?”
Monitor concomitant treatments.
Provide s tandardized meal
(s).  
6.2.4. Day 3
The following procedures will be completed:
Collect blood samples for PKanalysis of rivipansel 48hours after dosing on Day 1.
Assess sy mptoms by  sponta neous reporting of AE s and by  asking the subjects to 
respond to a non- leading questio
n such as “How do y ou feel?” 
Monitor concomitant treatments.
Provide standard ized meal(s) .  
6.2.5. Day 4
Collect blood samples for PKanalysis of rivipansel 72hours after dosing on Day 1.
Assess sy mptoms by  sponta neous reporting of AE s and by asking the subjec ts to 
respond to a non- leading question such as “How do y ou feel?” 
Monitor concomitant treatments.
Provide standard ized meal(s) .  
6.2.6. Day 5
Collect blood samples for PKanalysis of rivipansel 96hours after dosing on Day 1.
Conduct full physical examination.
Perform contraception check.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 31Collect supine 12- lead ECG.
Obtain single supine BP, pulse rate andtemperature .
Collect blood and urine specimens for s afety laboratory  tests after a fast of at least 
4hours .
Assess sy mptoms by  spontaneous reporting of AEs and by  asking the subjects to 
respond to a non
-leading question such as “How do y ou feel?” 
Monitor concomitant treatments.
Provide standard ized meal(s) .  
Disch arge from C RUconfinement.  
If a subject has an y clinically significant, stud y-related abnormal
ities at the conclusion of a 
scheduled inpatient portion of the study , the Pfizer medical monitor (or designated 
representative) should be notified and the subject may be asked to remain in the CRU until 
such abnormalities are no longer deemed clinically  significant, or it is considered safe for 
outpatient follow -up.  If the subject is unable or unwilling to remain in the CRU and/or when 
outpatient follow -up is deemed appropriate, the Pfizer medical monitor (or designated 
representative) should be so notifi ed, and the investigator should make every  effort to arrange 
follow -up evaluations at appropriate intervals to document the course of the abnormalities.
6.3.Follow -upContact
Each subje ct will have a follow -up phone call no earlier than 28 days and no later 
than 31 daysafter study  medication administration to assess for AEs and SAEs .  
6.4.Subject Withdrawal /Early Termination
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investi gator or sponsor for safety (see also the 
Withdrawal From the Study  due to Adverse Events section) or
behavioral reasons, or the 
inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given investigator site.  The earl
y termination visit applies only  to subjects 
who are randomized and then are prematurely  withdrawn from the study .
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  The i nvestigator or sit e staff should attempt to contact the subject twice.  After 
2attempts, CRU staff may send a registered letter.  If no response is received from the 
subject, the subject will be considered lost to follow -up.  All attempts to contact the subject 
and informa tion received during contact attempts must be documented in the subject’s 
medical record.   In an y circumstance, every  effort should be made to document subject 
outcome, if possible.  The investigator should inquire about the reason for withdrawal, 
request that 
the subject return for a final visit, if applicable, and follow- up with the subject 
regarding an y unresolved AEs .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 32It may  be appropriate for the subject to return to the clinic for final safet y assessments to be 
scheduled as earl y as practically feasib le following the decision to withdraw from the study .  
Subjects should be questioned regarding their reason for withdrawal.  At the earl y withdrawal 
visit, every  effort must be made to complete the following a ssessments:
Full physical examination , if there is a new or ongoing AE or clinicall y significant 
abnormal ph ysical finding from the last visit ;
Supine BP and pulse rate measurements
;
12-lead ECG measurement;
Blood and urine specimens for safety  laboratory tests after fasting for at least 4 hours ;
Blood sample for PK analy sis.
Lack of completion of all or an y of the withdrawal/ early termination procedures will not be 
viewed as protocol deviations so long as the subject’s safet y was preserved.
If the subject withdraws from the study  and also withdraws con sent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
Subjects who withdraw from t
he study  may  be replaced at the discretion of the investigator 
upon consultation with the sponsor .  
7.ASSESSMENTS
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances, outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the subject.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preven tive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study team must be informed of thes
e incidents in a timely  manner.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiati on of the study .  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 337.1.Safety
7.1.1. Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the STUDY 
PROCEDURES section of this protocol.   Additional laboratory  results may  be reported o n 
these samples as a result of the method of analy sis or the ty pe of anal yzer used by  the clinical 
laboratory ; or as derived from calculated values.  These additional tests would not require 
additional collection of blood.  Unscheduled safety laboratory  mea
surements may be 
obtained at an y time during the study  to assess any  perceived safety  concerns.
The laboratory  tests shown in Table 2 will be performed at the timepoints stated in the
Schedule of Activitie s.
Table 2. Safety Laboratory Tests
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)
PT/INRBUN/urea and Creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total b ilirubin
Alkaline phosphatase
Uric acid
Albumin
Total proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaFSHb
Urine drug testc
Serologic tests: HIV -1 
antibody, HBsAg and 
HCV antibodyd
Additional Tests (If 
required for assessment 
of potential Hy’s law 
cases)
AST, ALT (repeat)
Total bilirubin (rep eat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
Creatine kinase
GGT
PT/INR
Total bile acids
Acetaminophen drug 
and/or protein adduct 
levels
a Only if urine dipstick is positive for blood, protein, nitrites or leuk ocyte esterase.
b At screening only, in females who are amenorrheic for at least 12 consecutive months to assess childbearing potential. 
c At screening and Day 0only.
d At screening only.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 34The m inimum requirement for drug testing includes cocaine, tetrah ydrocannabinol 
(THC ), opiates /opioids, benzodiazepines, and amphetamines.
Subjects may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for subjects to receive study  
medicatio n. 
Any remaining serum/plasma fro m samples collected for safet y lab oratory  
measurement s at baseline and at all times after dose administration may be retained 
and stored for the duration of the study . Upon completion of the study , retained 
safet y samples may be used for the assessment of exploratory  safet y biomarkers or 
unexpected safet y findings.  These data will not be included in the clinical study  
report (CSR).  Samples to be used for this purpose will be shipped to either a Pfizer 
approved Biospecime n Banking Sy stem (BBS) facility  or other designated laboratory  
and retained for up to 1 year follow ing the completion of the study .
7.1.2. Physical Examinations
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistan t, or 
nurse practit ioner as acceptable according to local regulation s.  A full 
physical examination 
will include assessment of head, ears, ey es, nose, mouth, skin, heart and lung examinations, 
lymph nodes and gastrointestinal, musculoskeletal, and neurological s ystems.  The limited or 
abbreviated ph ysical examination will be focused on general appearanc eandthe respiratory  
and cardiovasc ular s ystems, andsubject -reported sy mptoms.
For measuring weight, a scale with appropriate range and resolution is used and must be 
placed 
on a stable, flat surface. Subjects must remove shoes, bulky  layers of clothing, and 
jackets so that only  light clothing remains.  They  must also remove the contents of their 
pockets and remain still during measurement of weight. 
7.1.3. Blood Pressure and Pulse Rate
BP and pulse rate will be measured at times specified in the STUDY PROCEDURES section 
of this protocol.  Additional collection times, or changes to collection times of BPand pulse 
rate will be permitted, as necessary , to ensure appropriate collection of safety  data.
Supine BP will be measured with the subject’s arm supported at the level of the heart , and 
recorded to the nearest mm Hg after approxi mately  5 minutes of rest.  The same arm 
(preferabl y the domina nt arm) will be used throughout the study . Blood pressure should not 
be taken from the arm with an intravenous infusion . 
Subjects should be instructed not to 
speak during measurements.  
The same properl y sized and calibrated BPcuff will be used to meas ure BPeach time.  The 
use of an automated device for measuring BP and pulse rate is acceptable ;however , when 
done manuall y, pulse rate will be measured in the brachial/radial artery for at least 
30seconds.  When the timing of these measurements coincide s with a blood collection, BP
and pulse rate should be obtained prior to the nominal time of the blood collection.  
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 357.1.4. Temperature
Temperature will be measured orally.  No eating, drinking or smoking is allowed for 
15minutes prior to the measurement.
7.1.5. Electr ocardiogram 
ECGs should be collected at times specified in the STUDY PROCEDURES section of this 
protocol.
All scheduled ECGs should be performed after the subject has rested quietly  for at least 
10minutes in a su pine position. 
To ensure safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.  If the QTcF interval is increased by  ≥45 msec from 
the baseline, or an absolute QTcF value is 500msec for a ny scheduled ECG, then 
2additional ECGs will be collected, approximately 2 to 4 minutes apart, to confirm the 
original measurement.  If either of the QTc F values from these repeated ECGs remains above 
the threshold value ( ie, ≥45 msec from the baseline , or500msec), then a single ECG must 
be repeated at least hourly  until QTc Fvalues from 2 successive ECGs fall below the 
threshold value that triggered the repeat measurement. 
If QTc Fvalues remain ≥500 msec (or ≥45msec from the baseline) for greater tha n 4hours 
(or sooner at the discretion of the investigator) or QTc Fintervals get progressively  longer, 
the subject should undergo continuous ECG monitoring.  A cardiologist should be consulted 
if QTc F
intervals do not return to less than 500 msec (or to < 45msec above the baseline) 
after 8 hours of monitoring (or sooner at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat measurements may  not be ne cessary  if a 
qualified medical provide r’s interpretation determines that the QTcF values are in the 
acceptable range.
7.2.Pharmacokinetics
7.2.1. Plasma for Pharmacokinetic Analysis of Rivipansel
During all study  periods, blood samples 4.0 mL  to provide a minimum of 1.5 mL plasma for 
PKanaly sis will be collected into appro priately  labeled tubes containing K 2EDTA at times 
specified in the STUDY PROCEDURES section of the protocol .  
The actual times may  change but the number of samples will remain the same.  All efforts 
will be made t o obtain the PKsamples at the exact nominal time relative to dosing.  
However, samples obtained within 10% of the nominal time (eg, within 6 minutes of a 
60
minute sample) from dosing will not be captured as a protocol deviation, as long as the 
exact time of the sample collection is noted on the source document and data collection tool 
(eg,case report form [ CRF ]/DCT ).
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 36Samples will be centrifuged at approximatel y 1700 ×g for about 10 minutes at 4 C.  
The plasma will be stored in appropriatel y labeled scre w-capped pol ypropylene tube 
at approximatel y -20
C within 1 -hour of collection. 
Samples will be analy zed using a validated anal ytical method in compliance with 
Pfizer SOPs
.  
The PK samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity .  An y deviations from 
the PK sample handling procedure (eg, sample collection and processing steps, 
interim storage or shipping conditions), including any  actions taken, must be 
documented and re ported to the sponsor.  On a case by  case basis, the sponsor may  
make a determination as to whether sample integrity  has been compromised.  Any  
deviation from the specified sample handling procedure resulting in compromised 
sample integrity will be conside red a protocol deviation.  
As part of understanding the PKof the study  drug, samples may  be used for 
metabolite identification and/or evaluation of the bioanaly tical method.  These data 
will be used for internal exploratory  purposes and will not be included in the CSR.  
7.2.2. Plasma for Unbound Fraction Determination of Rivipansel
On Day 1, ablood sample (10.0 mL to provide a minimum of 5.0 mLplasma )for PK
analysis will be collected into appropriatel y labeled tubes containing K 2EDTA at the time 
specified in theSTUDY PROCEDURES section of the protocol.  Sample will be anal yzed 
only if a PK 
difference in subject groups is observed.  
All efforts will be made to obtain the PKsampl eat the exact nominal time relat ive to dosing.  
However, a sample obtained within 10% of the nominal time (eg, within 6 minutes of a 
60 minute sample) from dosing will not be captured as a protocol deviation, as long as the 
exact time of the sample collection is noted on the source document a nd data collection tool 
(eg,CRF /DCT ).
Samples will be centrifuged at approximatel y 1700 ×g for about 10 minutes at 4 C.  
The plasma will be stored in appropriatel y labeled screw -capped pol ypropylene tube 
at approximatel y -20C within 1 -hour of collection. 
Samples will be analy zed using a validated anal ytical method in compliance with 
Pfizer SOPs.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 37The PK samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity .  An y deviations fr om 
the PK sample handling procedure (eg, sample collection and processing steps, 
interim storage or shipping conditions), including any  actions taken, must be 
documented and reported to the sponsor.  On a case by case basis, the sponsor may  
make a determin ation as to whether sample integrity has been compromised.  Any  
deviation from the specified sample handling procedure resulting in compromised 
sample integrity  will be considered a protocol deviation .  
As part of un derstanding the PKof the study  drug, s amples may  be used for 
metabolite identification and/or evaluation of the bioanaly tical method.  These data 
will be used for internal exploratory  purposes and will not be included in the CSR.  
7.3. Blood Volume
The total blood sampling volume for individual su bjects in this study  is approximately  
91mL.  The actual collection times of blood sampling may change .  Additional blood 
samples may  be taken for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not ex ceed 550 mL during an yperiod of 60consecutive 
days.
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event ( SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 types of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational exp osure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Non-serious AE All None
Exposure to the 
investigational product under 
study  during pregnancy  or 
breastfeeding, and 
occu pational exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy
(EDP) , exposure via 
breastfeeding, occupational 
exposure (regardless of 
whether associated with an 
AE)
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 38All observed or volunteered events regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for cl assification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available a utopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further info rmation may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 398.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject.  In addition, each study subject will be questioned about the 
occurrence of AEs in a non -leading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal section)
Withdraw al due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investigational product), thro ugh and including a 
minimum of 28 calenda r day safter the last administration of the investigational product.
For subjects who are screen failures, the active collection period ends when scree n failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after the active colle ction period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfize r concurs with that assessment.
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non- serious AE s and SAEs are recorded on the 
CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 408.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality  assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal re lationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, inc luding suspected unexpected serious adverse reactions, will be carried out 
in accordance wit h applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in phy
sical examination findings;
Hypersensiti vity;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 41Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP) ;
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; an d/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study, significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient h ospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 42Results in congenital anomaly /birth defect.
Or that is consider ed to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an e mergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hospitalization is defined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospitalization d oes not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 43Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;
Preplanned treatments or surgical procedures.  These should be no ted in the baseline 
documentation for the entire protocol and /or for the individual subject.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the proc edure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be r ecorded a s treatment of the 
AE.
8.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the ser iousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 44normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptibl e.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL Tand TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in e ither AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For subjects with baseline AST OR 
ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as nee ded, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on cli nical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.  .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 45In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma- glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also b e given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual histor y, 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E i nfection and liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reas on for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have ex cluded an alternative etiology .
8.4.2. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.2.1. Exposure During Pregnancy
For both unapproved/unlicensed produc ts and fo r marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is fou nd to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
andhas been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 46If a su bject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inha lation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery (see below for 
information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completio n (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a t ermination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fetus should be assessed by  gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital an omal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarria ge and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as rel ated or possibly  related to 
exposure to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants t o identify  developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 478.4.2.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with autho rized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.2.3. Occupational Exposure
An occupational exposure occurs when, during the performance of j ob duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the inves tigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT S AE Report 
Form is maintained in the investigator site file.
8.4.3. Medication Errors
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors .
Safety Event Recorded on the CRF Reported on the CT S AE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE) Only  if associated with an 
SAE 
8.4.3.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength. 
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of w hat is foreseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 48In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .  
9. DATA ANALYSIS/STATIS TICAL METH ODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a statistical analysis plan (SAP) , which will be 
maintained by  the sponsor.  Th
eSAP may modify  what is outlined in t he protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition or its 
analysis will also be reflected in a protocol amendment.
9.1.Sample Size Determination
Hepatic impairment s ubjects will be enrolled based on their Child -P
ugh score s at Screening
and Day 0.
Eight (8) subjects will be enrolled into each of the two study  groups (moderate hepatic 
impairment and health y with normal hepatic function ).  
This is an estimation study.  The sample size is based on recommendation sfrom the Food 
and Drug Administration (FDA )Guidance for Industry  “Pharmacokinetics in Patients with 
Impaired Hepatic Function: Study  Design, Data Analy sis, and Impact on Dosing and 
Labeling
.”23
9.2.Pharmacokinetic An alysis
The PK concentration population is defined as all subjects treated with study  drug who have 
at least 1 concentration measurement.
The PKparameter anal ysis population is defined as all subjects treated with study  drug who 
have at least 1 of the 
PKparameters of interest.
Analy sis of variance (ANOVA) will be used to compare the natural log transformed AUC inf
(if data permit), AUC lastand C maxbetween normal hepatic function group and the impaired 
hepatic function group. The geometric least squares mea n point estimate and the associated 
90% confidence intervals (CI s) for the difference of each comparison will be estimated. 
Rivipansel PK parameters AUC inf, Cmax, AUC last, Tmax, t½, 
CL Vsswill be summarized
descriptivel y by group .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 49Boxplots of mean, media n and individual subject parameters will be made across all the 
groups for AUC inf, AUC lastand C max.Concentrations will be listed and summarized 
descriptivel y by PK sampling time and group. Summary  profiles ( mean sand median s)of the
concentration -time data will be plotted across different groups. Individual subject 
concentration time profiles will be also presented. For summary  statistics and summary  plots 
by sampling time, the nominal PK sampling time will be used, for individual subject plots by  
time, the actual PK sampling time will be used.
9.2.1. Plasma
PK parameters of rivipansel following 
single dose administration will be derived from the 
concentration -time profiles as follows:
Param eter Definition Method of Determ ination
AUC last Area under the plasm a concentration -time 
profile from time zero to time of the last 
quantifiable concentration (C last)Linear/Log trapezoidal rule
AUC infaArea under the plasma concentration -time 
profile from time zero extrapolated to 
infinite timeAUC last+ (C last*/kel), where C last* is the 
predicted plasma concentration at the 
last quantifiable time point estimated 
from the log -linear regression analysis
Cmax Maximum plasma concentration Observed directly from data
Tmax Time for C max Observed directly from data as time of 
first occurrence
t½aTerminal elimination half -life Log e(2)/k el, where k elis the terminal 
phase rate constant calculated by a linear 
regression of the log -linear 
concentration -time curve. Only those 
data points judged to describe the 
terminal log -linear decline will be used 
in the regression
CLaTotal clearance of drug from plasma Dose/AUC inf
VssaVolume of distribution at steady state CL * MRT, where MRT is the mean 
residence time
aIf data permit
Actual PK sampling times and non-compartmental methods will be used in t he derivation of 
PK parameters.
9.3.Safety Analysis
AEs, ECG s, BP , pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the s afety of subjects.  An y safety laboratory , 
ECG , BP, orpulse rate abnormalities of potential clinical concern will be described.  Safet y 
data will be presented in tabular and/or graphical format and summarized descriptivel y, 
where appropriate.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 50Medical history  and information from phy sical and/or neuro logical examination collected 
during the course of the study  will be considered source data and will not be required to be 
reported , unless otherwise noted.  However, any  untoward findings identified on phy sical 
and/or neurologic alexamination s conducted during the active collection period willbe 
captured as an 
AE, if those findings meet the definition of AE s. Data collected at screening 
that are used for inclusion/exclusion criteria, such as laboratory  data, ECGs ,and vital signs 
will be considered sourc e data, and will not be required to be reported , unless otherwise 
noted.  Demographic data collected at s creening will be reported .
9.4. Interim Analysis 
No formal interim anal ysis will be conducted for this study .However, as this is a 
sponsor -open stud y,the sponsor may  conduct unblinded reviews of the data during the 
course of the stud y for the purpose of safet y assessment, facilitat ingdose-escalation 
decisions, facilitating PK/PD modeling, and/or support ingclinical development.  Unblinded 
results will b e reviewed by  a designated limited number of s ponsor colleagues within the 
study  team. Refer to the study  Data B linding Plan and/or SAP for specific details including 
delineation of study  team members who will be involved in these unblinded reviews as wel l 
as steps to be instituted ahead of initiation of an y unblinded review to ensure study  integrity  
is maintained.
9.5.Data Monitoring Committee 
This study  will not use a data monitoring committee .
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study  conduct for studies 
conducted at non- Pfizer investigator sites,toensure that the protocol and Good Clinical 
Practices ( GCPs) are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs /DCT sareaccurate.  T he investigator and institution 
will allow Pfizer monitors/auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.  This verification may  also occur 
after stud y completion.
During study  conduct and/or after study  completion, the investigator site may  be subject to 
review b y the IRB/EC, and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/o r to inspection by  appropriate regulatory  
authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
orits age nts to prepare the 
investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection. The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the study  
data and the subject’s medical records. The investigator will promptly  provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 51authorities, the investigator will provide Pfizer or its agent s with an opportunity  to review 
and comment on responses to any  such findings.
For studies conducted at non -Pfizer investigator sites, it is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and poss ible audits or 
inspections and that sufficient time is devoted to the process.
11.DATA HANDLING AND RE CORD KEEPING
11.1. Case Report Forms/ Data Collection Tools/ Electronic Data Record
As used in this protocol, the term CRF /DCT should be understood to refer to eith er a paper 
form or an electronic data record or both, depending on the data collection method used in 
this study .
A CRF/DCT is required and should be completed for each included subject.  The completed 
original CRFs/DCTs are the sole propert y of Pfizer and should not be made available in an y 
form to third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and r eporting of all clinical, 
safet y,and laboratory  data entered on the CRFs/DCTs and an y other data collection forms 
(source documents) and ensuring that they  are accurate, authentic/original, attributable, 
complete, consistent, legible, timely  (contemporane ous), enduring
,and available when 
required.   The CRFs /DCTs must be signed by the investigator or by  an authorized staff 
member to attest that the data contained on the CRFs /DCTs aretrue. Any corrections to 
entries made in the CRFs /DCTs orsource documen ts must be dated, initialed and explained 
(if necessary ) and should not obscure the original entry .
In most cases the source documents are the hospital or the ph ysician's chart.  I n these cases, 
data collected on the CRFs /DCTs must match those charts. 
In some cases, the CRF /DCT may also serve as the source document.  In these cases, a 
document should be available at the investigator site andat Pfizer 
thatclearly  identif iesthose 
data that will be recorded on the CRF /DCT ,and for which the CRF /DCT will st and as the 
source document .  
11.2. Record Retention
To enable evaluations and/or inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to l ink records, e g,CRFs /DCTs and hospital records), all original 
signed informed consent documents , copies of all CR Fs/DCTs
, safety  reporting forms, source 
documents, detailed records of treatment disposition, and adequate documentation of relevant 
correspon dence (e g,letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICHguidelines, according to local 
regulations, or as specified in the clinical study  agreement (CSA) , whichever is longe r.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 52If the investigator becomes unable for any  reason to continue to retain study records for the 
required period (e g, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfize r, such as another 
investigator, another institution, or to an independent third part y arranged by Pfizer.
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informe d consent documents, and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file .  Copies of I
RB/EC approvals should be 
forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and re gulatory  
requirements, a ndthe general pri nciples set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH G uidelines for Good Clinical Practice , and the Declaration of 
Helsinki. 
12.3. Subj ect Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where 
required b y laws. 
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
names, address es,  and other identifiable data will be replaced by numerical code sbased on a 
numbering sy stem provided by  Pfizer in order to de -identify  
study subjects. The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’ snumerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subje cts’personal data consistent 
with applicable privacy  laws .
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 53The informed consent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .
The informed consent document sused during the informed consent process and an y subject 
recruitment materials must be reviewed and approved by  
Pfizer , approved by  the IRB/EC
before use , and available for inspection.
The investigator must ensure that each st udy subjec t isfully  informed about the nature and 
objectives of the stud y and possible risks associated with participation. 
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject ,before an y study-specific activity  is performed , unless a waiver of 
informed consent has been granted b y an IRB/EC .  The investigator will retain the original of 
each sub ject's signed consent document.
12.4. Reporting of Safety I
ssues and S erious B reaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory authorit y in any  area of the world, or if the investigator is aware of any  new 
information thatmight influence the evaluation of the benefits a nd risks of the investigational 
product, Pfizer should be informed immediately
. 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard , and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in the United States
Last subject last visit ( LSLV)is defined as the date the investigator reviews the last subjec t’s 
final safet y data and determines that no further evaluation is required for the subject to 
complete the trial.   
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinio n of the IRB/EC, or investigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
rivipansel at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 7 days.  As directed by  Pfizer, all study  materials must be collected and 
all CRFs/DCTs completed to the greatest e xtent possible.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 5415.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials .gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com , and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US B asic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patien ts)that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult p opulations or within 6 month s of the PCD for studies in pediatric 
populations.
PCDis defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study
concluded according to the pre -specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are su bmitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 month s of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual patients have been removed) on www.pfizer.com for Pfizer- sponsored 
interventional studies at the same time the US Basic Results document is posted to 
www.clinicaltrials.gov .
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  a 
principal investigator of the results of the study based on information collected or generated 
by theprincipal investigator, whether or not the results are favorable to the Pfizer product.
However , to ensure against inadvertent disclosure of c onfidential information 
or unprotected 
inventions, the i nvestigator will provide Pfizer an opportunity  to review any  proposed 
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 55publication or other t ype of disclosure of the results of the s tudy (collectively , “publication”)
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 days before it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 days.
The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfi zer product -related information 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results .
If the study is part of a multi -centerstudy , the i nvestigator agrees that the first publication is 
to be a joint publication coveri ng all investigator sites, and that an y subsequent 
publications 
bythe 
principal i nvestigator will refer ence that primary  publication . However, if a joint 
manuscript has not been submitted for publication within 12 months of completion or 
termination of t he study at all participating sites, the investigator is free to publish separatel y, 
subject to the other requirements of this section.
For all publications relating to the s tudy, the i nstitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the C SAbetween Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the C SA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subject s, and the CSA will control as to all other 
issues.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 5616.REFERENCES
1. Centers for Disease Control and Prevention Sickle Cell Disease homepage. Available 
at: http://www.cdc.gov/ncbddd/sicklecell/data.html.  Accessed February  12, 2014.  
2. Davis H, Roscoe M, Moore J, et al. Cost of hospitalizations associated with sickle cell 
disease in the US. Public Health Rep . 1997;112:40-3.
3. Stuart MJ, Nagel RL . Sickle -cell disease. Lancet . 2004;364:1343 -60.
4. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future 
promise. J Clin I nvest . 2007;117:850 -8.
5. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk 
factors. N Engl J Med. 1991;325:11-6.
6. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021 -30.
7. American Academy  of Pediatrics, Section on Hematology /Oncolog y and Committee on 
Genetics. Health supervision for children with sickle cell disease. Pediatrics . 
2002;109:526-35.
8. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin Nort h Am . 
2005;19:785 -802.
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease --Life 
expectancy  and risk factors for earl y death. N Engl J Med. 1994;330(23):1639 -44.
10. Smith WR, Penberthy  LT, Bovbjerg VE, et al. Daily  assessment of pain i n adults with 
sickle cell disease. Ann Intern Med . 2008;148(2):94-
101.
11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 
1997;337:762-9.
12. Okpala I. Leukocy te adhesion and the pathophy siology  of sickle cell disease. Curr Opin 
Hematol .2006;13:40-4.
13. Blum A, Yeganeh S, Peleg A, et al. Endothelial function in patients with sickle cell 
anemia during and after sickle cell crises. J Thromb Thromboly sis. 2005;19(2):83 -6.
14. Kato GJ, Marty r S, Blackwelder WC, et al. Levels of soluble endothelium- derived 
adhesion molecules in patients with sickle cell disease are associated with pulmonary  
hypertension, organ d ysfunction, and mortality . Br J Haematol . 2005;130:943-53.
15.
Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sic kle 
cell vascular occlusion: A new paradigm. Proc Natl Acad Sci . 2002;99:3047-51.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 5716. Kaul DK, Hebbel RP. Hypoxia/reox ygenation causes inflammatory  response in 
transgenic sickle mice but not in normal mice. J Clin I nvest . 2000;106(3):411-20.
17. Tedder TF, Steeber DA, Chen A, et al. The selectins: vascular adhesion molecules. Br J 
Rheumatol . 1995;34:1101-4.
18. Ebnet K, Vestweber D. Molecular mechanisms that control leukocy te extravasation: 
The selectins and chemokines. 
Histochem Cell Biol . 1999;112:1-23.
19. Chen S, Sprin ger TA. Selectin receptor -ligand bonds: Formation limited by  shear rate 
and dissociation governed by  the Bell model. 
Proc Natl Acad Sci . 2001;98:950 -5.
20. Blann AD, Nadar SK, L ip GYH. The adhesion molecule P- selectin and cardiovascular 
disease. Eur Heart J . 2003;24:2166 -79.
21. Kansas GS. Selectins and their L igands: Current concepts and controversies. Blood . 
1996;88: 3259
-87.
22. Schubert TT. Hepatobiliary  system in sickle cell disease.  Gastroenterology . 
1986;90 :2013 -21.
23. Guidance for Industry : Pharmacokinetics in p atients with impaired hepatic 
function -Study  design, data anal ysis, and impact on dosing and labeling. FDA 
Guidance, March 2011.
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 58Appendix 1. Determination of Encephalopathy for the Calculation of the Child Pugh 
Score
For the calculation of the portosy stemic encephal opathy (PSE) index the parameters are 
evaluated or determined as follows:
A = Degree of consciousness
According to the given grading of the table (clinical estimation of the investigating 
physician) .
B= Number Connection Test
According to the table
C= Tremor
According to the table
D= Ammonia concentration in venous blood
According to the table normal values: 25 -94g/dL
The weighting is according to the given formula 3 ×A+B+C+D, and the index calculated by  
multiplication by  100 and division by  24(see bel ow).
In deviation from the PSE index form, however, a maximum of only  24score can be attained 
in total (not 25).
The evaluation was then done according to the following grading:
PSE-Index (%)
Normal:
0: no encephalopathy
Moderate:
1-25: encephalopath y gra de I
26-50: encephalopath y grade II
Severe:
51-75: encephalopath y grade III
76-100: encephalopath y grade IV grade severe
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 59Portosystemic Encephalopathy (PSE) Examination
PSE-Index
A Grade of cons ciousness
0= no abnormalit y
1= slight absence, phobia, euph oria, shortened attention
2= letharg y, chronotaraxis, personality  change, strange behavior
3= somnolence, semistupor
4= coma
B Number of Connection test
0= <30 sec
1 = 31-50 sec
2 = 51-
80sec
3 = 81-
120sec
4= >120 sec
C Tremor (arms and han ds, ca 30 sec stretched)
0 =no tremor
1= rare tremor
2 =occasional tremor, not regularl y
3= frequent tremor
4= continuous tremor
D Ammonia Concentration in venous blood 
0= 10% elevated above ULN
1= 11
-60% elevated above ULN
2= 61 - 86% elevated above ULN
3= 87 -123% elevated above ULN
4= >124% elevated above ULN
PSE-sum = 3×A+B+C+D (max 24 scores) 
PSE-Index (%) = ( PSE-sum x 100)/24
26-50: encephalopath y grade II
Severe:
51-75: encephalopath y grade III
76-100: encephalopath y grade IV grade severe
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 60Appendix 2.Abbreviations 
The following is a list of abbreviations that may  be used in the protocol.  
Abbreviation Term
AE adverse event
Abs absolute
ACS acute chest sy ndrome
ADR Adverse Drug Reaction
ALT alanine transaminase
ANOVA analysis of variance
AST aspartate transaminase
AUC area under the curve
AUC inf area under the concentration -time curve from time 0 to infinity
AUC last area under the concentration -time curve from time 0 to the time of the 
last quantifiable concentration
BBS Biospecimen Banking System
BMI body  mass index
BP blood pressure
BPM beats per minute
BUN blood urea nitrogen
CI confidence interval
CL/F apparent oral clearance
CL r renal clearance
Cmax peak or maximum observed concentration
CO 2 carbon dioxide (bica rbonate)
CRF case report form
CRU clinical research unit
CSA clinical study  agreement
CSR clinical study  report
CT computed tomograph y
CTA clinical trial application
DCT data collection tool
DILI drug-induced liver injury
EC ethics committee
ECG electrocardiogram
EDP exposure during pregnancy
EDTA edetic acid (eth ylenediaminetetraacetic acid)
eGFR estimated glomerular filtration rate
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States)
FSH follicle -stimulating hormone
GCP Good Clinical Practice
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 61Abbreviation Term
GGT gamma -glutamy l transpeptidase
GMI Glycomimetics
Hb hemoglobin
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICH International Conference on Harmonisation
ID identification
IND investigational new drug application
INR international normalized ratio
IPM Investigational Product Manual
IRB institutional review board
IUD intrauterine device
IV intravenous
K2EDTA dipotassium ethy lene diamine tetraacetic acid
LFT liver function test
LSLV last subject last visit 
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MDRD Modification of Diet in Renal Disease
MRI magnetic resonance imaging
N/A not applicable
PCD primary  completion date
PD pharmacod ynamic
PK pharmacokinetic (s)
PT prothrombin time
QTc QT corrected for heart rate
QTcF QTcusing Fridericia’s formula
RBC red blood cell
SAE serious adverse event
SAP statistical analysis plan
SCD Sickle Cell Disease
SD standard deviation
SOP standard operating procedure
SRSD single reference study  document
t½ terminal half -life
TEAE treatment -emergent adverse event
TIPS transjugular in trahepatic portosy stemic shunt
Tmax time to reach maximum concentration
THC tetrah ydrocannabinol
TBili total bilirubin
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)
PF-06460031 
B5201006
Final Protocol, 27 June 2016
Page 62Abbreviation Term
ULN upper limit of normal
US United States
VOC vaso-occlusive crisis
Vss volume of distribution at steady  state
WBC white blood c ell
090177e18db60716\0.1\Draft\Versioned On:13-Feb-2018 08:35 (GMT)